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Abstract
Urinary tract infections after JJ stent insertion are among the most common complications, and the associated microorgan-
isms carry more antibiotic resistance determinants than those found in urine prior to stent insertion. In line with the trends 
in healthcare epidemiology which implicate multi-resistant microorganisms in a plethora of healthcare-associated infections, 
prosthetic stent material also represents an ideal milieu for biofilm formation and subsequent infection development with 
resistant bacterial agents. Here we describe a case of a 73-year-old Caucasian woman presenting with urinary tract infection 
after JJ ureteric stent insertion due to ureteric obstruction and hydronephrosis of her left kidney. Extensive microbiological 
work-up and comprehensive molecular analysis identified the putative microorganism as carbapenem-resistant Enterobacter 
aerogenes carrying New Delhi metallo-beta-lactamase 1 (NDM-1). This is a first literature report implicating such exten-
sively resistant strain of this species in early indwelling ureteric stent complications, and also the first report of NDM-1 in 
Enterobacter aerogenes in Croatia and Europe.
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Introduction
The JJ ureteric stents (also known as double-J stents) are 
an indispensable part of modern urological treatment arma-
mentarium [1]. Although originally used to treat fistulas or 
ureteric obstructions, the indications have expanded substan-
tially. However, different complications following JJ stent 
insertion may ensue, and urinary tract infections are on the 
forefront as the most common complication in females (and 
among the most common in men) [2].
Generally, bacteria isolated from urine following stent 
insertion and directly from the stents demonstrate more 
antibiotic resistance than those cultured from urine prior 
to stent insertion [3]. Albeit literature descriptions of exact 
pathogens causing these infections are scarce, the value of 
exact microbiological characterization (even on the molecu-
lar level) primarily lies in the adequate treatment decision 
making [4]. Moreover, certain microorganisms may prompt 
the formation of biofilms and encrustations on inserted 
stents, resulting in bacteriuria and urinary tract infection [5].
This is the first literature report of carbapenemase-pro-
ducing organism originating from the JJ stent, pointing to the 
significance of artificial, prosthetic material as a source of 
extensively drug-resistant bacteria, and also the first report 
of New Delhi metallo-β-lactamase 1 (NDM-1) producing 
Enterobacter aerogenes (E. aerogenes) in Croatia and (to 
our knowledge) in Europe.
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Case report
Due to the obstruction of the upper urinary tract caused by 
ureteroliths (i.e. ureteral calculi) and hydronephrosis of the 
left kidney, a 73-year-old Caucasian female was subjected 
to the indwelling JJ ureteric stent insertion in October 
2017 to re-establish the patency of the ureter. There was 
no known immunodeficiency or risk factors in her medical 
history. Due to intermittent fever and increased inflamma-
tory markers (CRP of 192.5 mg/dL, total leukocyte count 
of 19.8 × 109/L, as well as 81% of segmented neutrophils 
in the differential blood count), the patient was treated 
with ciprofloxacin 15 days prior to the procedure (followed 
by the improvement in the aforementioned parameters), 
while ceftriaxone was prescribed as a peri-interventional 
antimicrobial coverage. Shortly after stent placement 
a purulent content was observed in her left ureter, and 
15 days later a ureteral calculus (approximately 8 mm in 
diameter) was identified adjacent to the inserted JJ stent. 
Additionally, an increased number of polymorphonuclear 
leukocytes in urinary sediment prompted a detailed urine 
investigation.
Urine culture revealed a pure growth of Gram-nega-
tive bacterium identified as E. aerogenes by conventional 
biochemical testing and matrix-assisted laser desorption 
ionization-time of flight (MALDI-TOF) mass spectrom-
etry. The antimicrobial susceptibility to a wide range of 
antibiotics was determined by disk diffusion and broth 
microdilution method. Phenotypic methods were used to 
detect extended spectrum β-lactamases (ESBLs), plasmid-
mediated AmpC β-lactamases and carbapenemases. The 
transferability of meropenem resistance was determined by 
conjugation (broth mating method) employing Escherichia 
coli (E. coli) A15  R− strain resistant to rifampicin and E. 
coli J65 resistant to sodium azide [6].
The genes conferring resistance to β-lactams includ-
ing broad spectrum and extended-spectrum β-lactamases 
(blaSHV, blaTEM, blaCTX−M and blaPER−1), plasmid-medi-
ated AmpC β-lactamases, class A carbapenemases (blaKPC, 
blaSME, blaIMI, blaNMC,), class B metallo-β-lactamases 
(blaVIM, blaIMP and blaNDM), carbapenem hydrolyzing 
oxacillinases (blaOXA−48) and fluoroquinolones (qnrA, 
qnrB, qnrS) were determined by polymerase chain reac-
tion (PCR) using protocols and conditions as described 
previously [7]. Amplicons were column-purified with 
Qiagen DNA purification kit (Inel, Zagreb, Croatia) and 
sequenced in Eurofins sequencing services (Graz, Austria). 
PCR-based replicon typing was applied to type the resist-
ance plasmids carrying carbapenemase genes [8]. Plasmid 
extractions from transconjugant strains were subjected to 
PCR for carbapenemase detection (MBL and OXA-48) to 
determine the location of blaCARB genes.
The isolate was resistant to β-lactam antibiotics and gen-
tamicin, but susceptible to colistin and fosfomycin (Table 1). 
It was classified as extensively drug resistant according to 
Magiorakos et al. [9]. Double disk synergy test and com-
bined disk test with clavulanic acid were positive, suggest-
ing the production of an ESBL. Combined disk test with 
EDTA was positive, confirming the MBL production. The 
isolate transferred meropenem resistance to E. coli recipient 
strains with the frequency of  10−3. Resistance to gentamicin, 
sulphamethoxazole and tetracycline has been co-transferred 
alongside with meropenem resistance. PCR was positive 
with primers specific for NDM and TEM β-lactamases. 
Sequencing of the PCR products of the clinical isolate and 
the respective transconjugant experiment revealed TEM-1 
and NDM-1. The transconjugant exhibited slightly lower 
minimum inhibitory concentration (MICs) of carbapen-
ems and expanded-spectrum cephalosporins compared to 
the clinical isolate. The plasmid extraction from donor and 
recipient strain was positive for HI2 incompatibility group 
of plasmids.
Such extensive microbiological work-up showed that 
this isolate was carbapenem-resistant E. aerogenes carry-
ing NDM-1 resistance determinant. The treatment was pre-
scribed according to the respective sensitivity pattern (with 
subsequent negative urine culture results) and the patient 
was scheduled for extracorporeal shockwave lithotripsy 
(ESWL).
Table 1  Minimal inhibitory concentrations (MICs) of various antimi-
crobial agents tested against isolated Enterobacter aerogenes strain 
and against transconjugant A15  R− E. coli strain
Antimicrobial agent MIC (mg/L) E. 
aerogenes 8020
MIC (mg/L) 
transconjugant E. coli 
A15  R−
Amoxicillin > 128 > 128
Amoxicillin/clavulanate > 128 32
Piperacillin > 128 > 128
Piperacillin/tazobactam > 128 64
Cefazolin > 128 > 128
Cefuroxime > 128 64
Ceftazidime > 128 32
Cefotaxime > 128 64
Ceftriaxone > 128 64
Cefepime > 128 16
Ertapenem > 128 32
Imipenem > 128 16
Meropenem > 128 16
Gentamicin 32 8
Ciprofloxacin 2 0.25
Colistin 0.12 0.06
Fosfomycin 64 8
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Discussion
NDM-1-producing E. aerogenes is extremely rare and, to 
our knowledge, has not been described in Europe thus far. 
This extensively resistant isolate was previously found 
in Asian countries (more precisely in India, China and 
Vietnam), where it was responsible for different types of 
infections [10–12]. Although there are studies involving 
NDM-1-producing Enterobacteriaceae in urinary pathol-
ogy and even urosepsis [13], this is the first report linking 
NDM-1-producing E. aerogenes to urinary tract infection 
after JJ stent insertion, with substantial peri-interventional 
and post-interventional drug selection ramifications.
Most patients usually receive one dose of gentamicin 
or ceftriaxone as prophylaxis prior to stenting procedure 
[2]; in this case, the latter was prescribed as peri-interven-
tional antimicrobial coverage. Other authors recommend 
fluoroquinolones for that purpose [3]. However, all those 
recommendations would have to be reconsidered in case 
of increased encounters with carbapenemase-producing 
microorganisms related to JJ stenting, as described here.
Moreover, this type of pathogen-stent correlation could 
be also considered a biofilm infection, complicating treat-
ment attempts even further. The surface of ureteral stents 
represents an ideal milieu for biofilm formation, which 
in turn provides nutrients to implicated microorganisms 
and protects them from phagocytes and antibiotics [5]. 
Since biofilms are generally seen as a major limiting fac-
tor for the long-term usage of ureteral stents [5], many 
research endeavours have focused on its pathogenesis 
and prevention; still, studies concentrating on potential 
inducing microorganisms are lacking. Hence the role of E. 
aerogenes as a potential biofilm inducer in ureteral stents 
warrants further research.
The prevalence of the carbapenemase-producing Enter-
obacteriaceae is highly variable across Europe, with high 
prevalence found in Greece, Israel, Italy and Turkey, and 
low prevalence noted in Nordic countries, Germany, Swit-
zerland, and the Czech Republic [14]. Enterobacter aero-
genes has been touted as an important opportunistic and 
multi-resistant bacterial pathogen for humans in hospital 
wards, largely described during several outbreaks of hospi-
tal-acquired infections in Europe [15]. NDM-1 producers 
have been identified on all continents with a direct link to 
Indian subcontinent in a majority of cases; furthermore, it 
has been shown that the Middle East and the South Euro-
pean states (including Croatia) may act as secondary res-
ervoirs of NDM-1 producers [15].
Regarding the local situation in Croatia, the first car-
bapenem-resistant Enterobacteriaceae family member 
was NDM-1 producing Klebsiella pneumoniae (K. pneu-
moniae) [16]. Shortly after this description an increase 
of carbapenem-resistant microorganisms was observed, 
when a multicentre study on carbapenem resistance in 
Enterobacteriaceae revealed the predominance of VIM-1 
β-lactamase in two large Croatian hospital centres, as well 
as sporadic occurrence of NDM-1 [17]. A study conducted 
2 years later demonstrated an increase of NDM-1-produc-
ing Enterobacteriaceae, but predominantly Enterobacter 
cloacae and K. pneumoniae [18].
The isolate described here was phenotypically positive 
for ESBL; however, sequencing of TEM product identi-
fied TEM-1 which is a broad spectrum and not extended-
spectrum β-lactamase. Such false-positive results in pheno-
typic tests can be attributed to hyperproduction of TEM-1 
β-lactamase. In conclusion, exact pathogen identification 
with molecular determination of resistance determinants is 
pivotal when addressing infective sequelae after the inser-
tion of JJ stent or other prosthetic devices.
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